In a clinical trial of advanced esophageal cancer treated with pembrolizumab (anti PD-1) as ≥ second-line therapy, gene expression profiling revealed co-enrichment of LAG3 and IDO1 in PD-L1+ tumors, and high LAG-3 expression was associated with poorer progression-free survival (91). This evidence concerns the gene LAG3 and esophageal cancer.